SCHRODERS URGES ASTRAZENECA TO RESTART TALKS WITH PFIZER

     (The following press release from Schroders was received by e-mail. The  sender verified the statement.)  Schroders notes with disappointment the quick rejection by the AstraZeneca  Board of the latest offer from Pfizer and the decision of the Pfizer Board to  draw a premature  end to these negotiations by calling their latest proposal  Final.  As long term shareholders, we are strong believers in AstraZeneca and  the potential for its innovative growth pipeline, however, given the increase  in the offer we would encourage the AstraZeneca  management to recommence their  engagement with Pfizer, and subsequently their shareholders.